Analyse

Despite short‑term stock pressure from interest rates and supply issues, Korean pharma and biotech companies are pursuing M&A, tech exports and capacity investments, boosting fundamentals, says a Mirae Asset report.

While a weak won usually boosts exporters, pharma and biotech firms see mixed effects as foreign revenue growth is offset by rising foreign‑currency costs for raw materials, debt and liabilities.

Klick Health completes its third acquisition in 18 months, buying Oxford PharmaGenesis to expand globally and deepen scientific expertise.